Search Results
May 26, 2026, 08:06 ET DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc. Announce Early Results of Cash Tender Offer for 5.875% Senior Secured Notes Due 2027
25461L AA0 / US25461LAA08 U2541M AA8 / USU2541MAA81$1,711,000,000
More news about: DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc.
May 19, 2026, 16:15 ET MAA Announces Quarterly Common Dividend
advance of MAA's earnings announcement that is expected to be made on July 29, 2026.About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
May 13, 2026, 16:05 ET Precigen Reports First Quarter 2026 Financial Results and Business Updates
NCT06538480).MAA under review by the EMA: Following submission in November 2025, the Marketing Authorization Application for PAPZIMEOS for the treatment of adults
More news about: Precigen, Inc.
May 11, 2026, 08:47 ET DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc. Announce Tender Offer for Up to $1,400,000,000 in Aggregate Principal Amount of Their 5.875% Senior Secured Notes Due 2027
25461L AA0 /US25461LAA08U2541M AA8 / USU2541MAA81$1,711,000,000
More news about: DirecTV
May 11, 2026, 04:40 ET This Mother's Day, SBI Life honours the quiet strength of a mother's instinct through its 'Bin Samjhaaye, Sirf Maa Samajhti Hai' campaign
often even before they fully surface. SBI Life Insurance brings this powerful truth to life through its Mother's Day film, 'Bin Samjhaaye, Sirf Maa Samajhti Hai'; a tribute to the quiet emotional strength that makes a mother the first source of comfort, confidence, and belief in every family.
More news about: SBI Life Insurance
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
DOVBLERON®. Additionally, the Company, along with its partner, Eisai, announced in March 2026 that the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency for full approval consideration with a standard review timeline.About ROS1+
More news about: Nuvation Bio Inc.
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
March 2026, Nuvation Bio announced with Eisai Co., Ltd. that the European Medicines Agency (EMA) had validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1+ NSCLC. The filing is being considered for full approval and will follow a standard review timeline.On
More news about: Nuvation Bio Inc.
May 04, 2026, 16:05 ET Cryoport Reports First Quarter 2026 Financial Results
766In Q1 2026, four Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. During the first quarter, Cryoport's customer, Rocket Pharmaceuticals, received U.S. Food and Drug Administration (FDA) accelerated
More news about: Cryoport, Inc.
May 04, 2026, 08:00 ET Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details
More news about: Acurx Pharmaceuticals, Inc.
Apr 30, 2026, 21:07 ET TLX101-Px (Pixlumi®) MAA Accepted in Europe
2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate[1],
More news about: Telix Pharmaceuticals Limited
Apr 30, 2026, 12:38 ET Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Apr 30, 2026, 12:30 ET Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Apr 29, 2026, 16:15 ET MAA REPORTS FIRST QUARTER 2026 RESULTS
31, 2026. During the first quarter of 2026, MAA completed the development of MAA Breakwater located in Tampa, Florida and MAA Liberty Row located in Charlotte, North Carolina.MAA funded approximately $100 million of costs for current and planned development projects,
More news about: MAA
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
discontinued operations Targeting Talicia global market expansion in the UK with submission of fast-track Marketing Authorisation Application (MAA) imminentR&D pipeline focus and progress: RHB-204 for Crohn's disease (CD) advancing in
More news about: RedHill Biopharma Ltd.
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
DOVBLERON®. Additionally, Nuvation Bio, along with its partner Eisai, announced in March 2026 that the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency and accepted for full approval consideration with a standard review timeline.To
More news about: Nuvation Bio Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Apr 15, 2026, 09:01 ET Parks Associates Announces Smart Spaces Advisory Board and Second Annual Property Innovation Awards
Angel GroupDave Lillis, CEO, DOORShahrukh Raheem, Head of Product & Analytics, AmazonJosh Siddon, VP, IT Architecture, MAA - Mid America Apartment CompanyTodd Thorpe, Director, Business Development, Cambium NetworksJoesar Watkins, Digital Resident Engagement
More news about: Parks Associates
Apr 09, 2026, 08:00 ET Oracle AI Database Raises the Bar for Availability and Security Across Mission-Critical Workloads
transparently take advantage of MAA Platinum-tier capabilities. Upgrading to Oracle AI Database 26ai on Exadata enables customers to immediately benefit from much faster failovers and less downtime with no additional effort. Enhanced Oracle AI Database 26ai capabilities for the MAA Platinum-tier include:
More news about: Oracle
Apr 02, 2026, 17:29 ET MAA Announces Date of First Quarter 2026 Earnings Release, Conference Call
GERMANTOWN, Tenn., April 2, 2026 /PRNewswire/ -- MAA (NYSE: MAA) announced today that the Company expects to release its first quarter 2026 results on Wednesday, April 29, 2026, after market close and will hold a conference
More news about: MAA
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Co-Rapporteur, the accepted MAA will be considered to support full approval."Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe," said David
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 25, 2026, 16:05 ET Precigen Reports Full Year 2025 Financial Results and Business Updates
NCT06538480).MAA under review by the EMA: Following submission in November 2025, the Marketing Authorization Application for PAPZIMEOS for the treatment of adults
More news about: Precigen, Inc.
Mar 17, 2026, 16:15 ET MAA Announces Quarterly Common Dividend
of MAA's earnings announcement that is expected to be made on April 29, 2026.About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
Mar 13, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's
More news about: Acurx Pharmaceuticals, Inc.